Ameet Sarpatwari

Ameet Sarpatwari, PhD, JD

Faculty Member of the Center
Member, HMS Center for Bioethics

Ameet Sarpatwari is an Assistant Professor of Medicine at Harvard Medical School and the Assistant Director of the Program On Regulation, Therapeutics, And Law (PORTAL) within the Division of Pharmacoepidemiology and Pharmacoeconomics at Brigham and Women's Hospital. His research draws upon his interdisciplinary training as an epidemiologist and lawyer and focuses on the effects of laws and regulations on therapeutic development, approval, use, and related public health outcomes.​Dr. Sarpatwari completed his undergraduate studies at the University of Virginia, where he was a Jefferson Scholar. He subsequently studied epidemiology at the University of Cambridge and law at the University of Maryland, where he was a John L. Thomas Leadership Scholar. Dr. Sarpatwari's current work focuses on risk evaluation and mitigation strategies, biosimilars, orphan drug policy, and drug development and pricing. In addition to his work with the Center for Bioethics, he also serves as a Faculty Affiliate with the Department of Health Policy and Management at the Harvard T.H. Chan School of Public Health, the Petrie-Flom Center for Health Law Policy, Biotechnology, and Bioethics at Harvard Law School, and the Behavioral Insights Group at the Harvard Kennedy School. He teaches an annual course on public health law at the Chan School.

Publications View
Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices.
Authors: Authors: Sarpatwari A, Lee MP, Gagne JJ, Lu Z, Dutcher SK, Jiang W, Campbell EG, Kesselheim AS.
Clin Pharmacol Ther
View full abstract on Pubmed
Evaluating The Impact Of The Orphan Drug Act's Seven-Year Market Exclusivity Period.
Authors: Authors: Sarpatwari A, Beall RF, Abdurrob A, He M, Kesselheim AS.
Health Aff (Millwood)
View full abstract on Pubmed
Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study.
Authors: Authors: Desai RJ, Sarpatwari A, Dejene S, Khan NF, Lii J, Rogers JR, Dutcher SK, Raofi S, Bohn J, Connolly J, Fischer MA, Kesselheim AS, Gagne JJ.
BMJ
View full abstract on Pubmed
Removing ERISA's Impediment to State Health Reform.
Authors: Authors: Fuse Brown EC, Sarpatwari A.
N Engl J Med
View full abstract on Pubmed
The Supreme Court Ruling in Sandoz v Amgen: A Victory for Follow-on Biologics.
Authors: Authors: Sarpatwari A, Gluck AR, Curfman GD.
JAMA Intern Med
View full abstract on Pubmed
Benefits, Limitations, and Value of Abuse-Deterrent Opioids.
Authors: Authors: Curfman GD, Beletsky L, Sarpatwari A.
JAMA Intern Med
View full abstract on Pubmed
Strategies That Delay Market Entry of Generic Drugs.
Authors: Authors: Vokinger KN, Kesselheim AS, Avorn J, Sarpatwari A.
JAMA Intern Med
View full abstract on Pubmed
Recalibrating Privacy Protections to Promote Patient Engagement.
Authors: Authors: Sarpatwari A, Choudhry NK.
N Engl J Med
View full abstract on Pubmed
Value-Based Pricing and State Reform of Prescription Drug Costs.
Authors: Authors: Hwang TJ, Kesselheim AS, Sarpatwari A.
JAMA
View full abstract on Pubmed
Active Surveillance of Follow-on Biologics: A Prescription for Uptake.
Authors: Authors: Sarpatwari A, Gagne JJ, Levidow NL, Kesselheim AS.
Drug Saf
View full abstract on Pubmed

Address: 
Brigham and Women's Hospital
General Medicine-OBC-3030, N2
1620 Tremont St
Boston, MA 02120